

Clinical Relationship between Lipid Profile and Glycohemoglobin Among Iraqi Patients with Type 2 Diabetes Mellitus

Esraa Abd AL-Karim Marouf*¹, Nuha A.Mohammed², Marwa Mohammed Sabri³

Department of Biology, College of Education for Pure Sciences, University of Al Anbar, Anbar, Iraq.

Department of Biology, College of Education for Pure Sciences, University of Al Anbar, Anbar, Iraq.

Department of Chemistry, College of Education for Pure Sciences, University of Al Anbar, Anbar, Iraq.

*Corresponding author:

E. A. Marouf ORCID ID Number: 0000-0002-6360-3648

ABSTRACT

HbA1c (A1c%) is the index of Glycohemoglobin state for a long duration. In addition, D.M., the ticking bombshell, has many effects on subjects' lifestyles, especially if they are obese. Where Lipid abnormalities (dyslipidemia) are very prevalent in type2 D.M. Dyslipidemia consequent to insulin impedance, the prime why of coronary atherosclerosis and ischemic heart disease, is considerably related to type2 D.M. Diabetes of type2 is a worldwide spreads epidemic where the number of patients increasing continuously and rapidly in both underdeveloped and progressing countries about the scientist. Atherosclerosis brings about the ischemic core disease and remains the primary reason for death and early disability in progressing nations, and its spread is constantly increasing in outgrowth countries. This study aimed to look into the relation between HbA1c and F.B.S. with lipid profile parameters (HDL, T.G., LDL, VLDL& T.C.) and determine their levels in type 2 D.M. patients. The present study appears that a direct proportional relation exists between dyslipidemia and high values of Glycohemoglobin (A1c%), which means the riskiness of high HbA1c% values with dyslipidemia rising may lead to atherosclerosis. Conclusion: the well glycemic dominance by antidiabetic treatment with a lifetime mode rearranging can minimize the danger of atherosclerosis and side effects.

Keywords: Type2 DM, Glycohemoglobin, lipid abnormalities, lipids profile, atherosclerosis.

1. Introduction

According to World Health Organization, Diabetic is a set of metabolic unrest owned properties of high blood sugar and anomalies in sugars, lipid, and protein metabolism. It results in flaws in insulin excretion, insulin allergy, or both. Chronic microvascular, macrovascular, and neuropathic multiples may happen⁽¹⁾. D.M. is the third most significant reason of dying around the world and is accountable for lot multiple effects on different members of the body^(2,3); it is like cancer⁽⁴⁾ and the severe effect of alcohol abuse and cigarette smoking that are well-known worldwide on body functions, especially liver and kidney⁽⁵⁾.

Away from carnal limitations and stress, D.M. increases economic encumbrance for the patients. Diagnosis of Diabetes mostly does not occur at a suitable time, and many subjects live with it until it is scouted by the lab tests carried out when the patient goes for therapy for some other illness. D.M. is considered a worldwide and nationally scourge, primarily because of the raised ratio of fatness. Fatness has widely become common in advanced nations, raising the spread of Diabetes⁽⁶⁾.

Obesity is turning out widely epidemic. Fatness is a freelance hazard operator for different heart diseases in both sexes⁽⁷⁾. Disturbances of fat metabolism are rumours& conspicuous in Diabetes, cirrhosis and cancer, which are significant dangerous operators for the extensive repetition of atheromatous multiples in the disease⁽⁸⁻¹⁰⁾. In diabetic patients, coronary heart disease is related to many pathological traits involving hypertension, hyperglycemia and flaw glycation of proteins, dyslipidemia and others from autonomic nervous diseases, endothelial and cardiovascular diseases⁽¹¹⁻¹³⁾. Through the past contract, cardiovascular diseases have become the singular most significant cause of doom worldwide. High T.C. values are

responsible for about 56% of ischemic heart disease and 18% of strokes, reach to 4.4 million dying yearly⁽¹⁴⁻¹⁶⁾.

In patients with type2 D.M., hyperlipidemia raises the danger of micro-vascular multiples, whereas hyperlipidemia is the leading danger agent to macro-vascular multiples⁽¹⁷⁻²⁰⁾. Various long-term studies conducted in various populations of various ethnicities, various eating nature, work and various life manners appear that most patients appear various diffusion and fashion of abnormalities of lipid in type 2 diabetes mellitus. However, they always appear well in the relation between HbA1c and personal lipid markers. Also, other studies conducted in various places of the world clarified the existence of different average results for different fat types, but all inferred that too elevated scale of dyslipidemia spread between type2 D.M. with different styles. These studies clarified that with exacerbation of HbA1c, the patient's lipid profile worsens⁽²¹⁾.

2. Results and discussion

2.1 Procedure

Our research was done on 105 volunteers who registered during attendance at our laboratories in Al-Ramadi Teaching Hospital/ Al-Anbar / Ramadi city. A105 subjects aged 35-65 years were split into three groups:

1-Group1 consists of 35 control subjects (healthy).

2-Group2 consists of 35 subjects who have HbA1c < 7% prediabetes and

3-Group3 consists of 35 subjects who have HbA1c > 7%.

Exception Criteria

- People with type 1 diabetes
- Hypothyroidism
- CKD, Nephrotic syndrome
- People who drink alcohol
- People who take lipid-lowering drugs
- Persons with high blood pressure who are using beta blockers or thiazide diuretics
- B.M.I. more than 25
- Smokers
- Cirrhosis or other liver diseases
- Hyperthyroidism / Hypothyroidism

2.2 Specimens

Individual consent was obtained from blood sample donors for the study purposes. For all 105 subjects, venipuncture specimens were withdrawn after at least 10 hr. fasting. Venipuncture specimens of all subjects were compiled in two types of tubes. One of them contains EDTA to measure HbA1c, while the other tube contains a gel material (non-anti-coagulant tube) to measure F.B.S. and lipid profile (T.C., T.G., HDL, VLDL and LDL). All information was recorded in detail, including lifestyle and symptoms of Diabetes mellitus type2, its duration, treatment and complications. Personal clinical history and eating habits were recorded. Smoking, drinking alcohol, exercise and other habits of the research volunteer were also recorded in the questionnaire. Comprehensive and accurate examinations were conducted for healthy volunteers and patients, such as liver, kidney, lipid, insulin resistance and thyroid tests, and heart, nervous and respiratory tests were recorded in the personal questionnaire for each volunteer.

2.3 Spectrophotometer APEL PD-303 JAPAN

All patients were measured F.B.S., and lipid profile (T.C., T.G., HDL, VLDL and LDL), where F.B.S. in blood was measured by spectrophotometry (GOD-POD) method^(22,23) and T.C. measure method in sera include using of three enzymes: (CE), (C.O.) and (P.O.D.)^(23,24,25) by using LiNEAR Chemicals. At the same time, the T.G. test method depends on the enzyme reaction lipoprotein lipase (L.P.L.) with T.G. in plasma or serum like other methods⁽²⁶⁾. HDL, VLDL and LDL were measured too.

2.4 Clover A1c System

The Clover A1c system is a fully automated boronate affinity assay. The HbA1c % of all patients was measured by the Clover A1c system.

2.5 Statistical Analysis

We used the Statistical Analysis System- S.A.S. program to reveal the effect variation groups in our study criteria. Minimum significant variation - L.S.D. test (Analysis of Variation- ANOVA) was used to compare the mean and standard deviation of results significantly.




Fig.1. Group2: Each value represents the mean ± S.E.M of F.B.S., CT, T.G. and LDL of type 2 diabetic patients (HbA1c < 7%) compared to the healthy group (control).




Fig.2. Group2: Each value represents the mean ± S.E.M of HbA1c%, HDL and VLDL of type 2 diabetic patients (HbA1c < 7%) compared to the healthy group (control).




Fig.3. Group3: Each value represents the mean ± S.E.M of F.B.S., CT, T.G. and LDL of type 2 diabetic patients (HbA1c > 7%) compared to the healthy group (control).




Fig.4. Group3: Each value represents the mean ± S.E.M of HbA1c %, HDL and VLDL of type 2 diabetic patients (HbA1c > 7%) compared to the healthy group (control).

3. Results

In our project, 105 people were chosen according to exception criteria which we determined before in the practical protocol part, where 105 people aged 35-65 years were split into three groups: group one (healthy), group two (HbA1c < 7%) and group three (HbA1c > 7%).

With regards to group two (HbA1c < 7%) of type 2 diabetic patients, their (mean ± S.E.M.) of F.B.S., CT, T.G. and LDL were (109.12 ± 6.21, 180.16 ± 18.75, 165.63 ± 20.63 and 104.51 ± 8.20) respectively as explained in figure1 and table (1).

Table 1: Represents the mean ± S.E.M of F.B.S., CT, T.G. and LDL of type 2 diabetic patients (HbA1c < 7%) compared to the healthy group (control).

Mean ± SD	S mg/d	mg/dl	mg/dl	L mg/dl
Healthy people G1	51 ± 0.36 2	103.6 ± 51	165 ± 13	108 ± 8
Patients G2 (HbA1c < 7)	109.12 ± 6.21 1	180.16 ± 18.75	165.63 ± 20.63	104.51 ± 8.20

Also, (mean ± S.E.M.) of HbA1c% <7% , HDL, and VLDL were (6.56 ± 0.32, 42.53± 2.98 and 33.13 ± 8.40) respectively, as explained in figure2 and table (2).

Table 2: Represents the (mean ± S.E.M) of HbA1c%, HDL, and VLDL of type 2 diabetic patients (HbA1c < 7%) compared to the healthy group (control).

Mean ± SD	HbA1c %	HDL mg/dl	VLDL mg/dl
Healthy people	6.56 ± 0.41	42.53 ± 2.98	33.13 ± 8.40
Patients G2 (HbA1c < 7)	6.56 ± 0.32	42.53 ± 2.98	33.13 ± 8.40

Moreover, in Group three (HbA1c > 7%) of type 2 diabetic patients, their (mean ± S.E.M.) of F.B.S., CT, T.G., and LDL were (220.08 ± 43.06, 270.18 ± 19.80, 210.33 ± 19.41 and 191.0 ± 16. 31) respectively as explained in figure number 3, and table3.

Table 3: Represents the mean ± S.E.M of F.B.S., CT, T.G. and LDL of type 2 diabetic patients (HbA1c > 7%) compared to the healthy group (control).

Mean ± SD	S mg/d	mg/dl	mg/dl	L mg/dl
Healthy people G1	86.51 ± 5.32	140.36 ± 10.51	90.65 ± 14.13	66.08 ± 4.78
Patients G3 (HbA1c >7)	220.08 ± 43.06	270.18 ± 19.80	210.33 ± 19.41	191.0 ± 16.31

Again (mean ± S.E.M.) of HbA1c%, HDL and VLDL were (11.32 ± 0.21, 37.53 ± 3.27 and 42.06 ± 9.32) respectively as explained in figure number 4 and table 4.

Table 4: Represents the (mean ± S.E.M) of HbA1c%, HDL, and VLDL of type 2 diabetic patients (HbA1c > 7) compared to the healthy group (control).

Mean ± SD	A1c %	HDL mg/dl	VLDL mg/dl
Healthy people	4.62 ± 0.41	58.15 ± 3.19	16.13 ± 1.89
Patients (HbA1c >7)	11.32 ± 0.21	37.53 ± 3.27	42.06 ± 9.32

However, group1 (the healthy group) their (mean ± S.E.M.) of F.B.S., CT, T.G. and LDL were (86.51 ± 9.32, 140.36 ± 10.51, 90.65 ± 14.13 and 66.08 ± 14.78) respectively as shown in figures number 1 & 3; also (mean ± S.E.M.) of HbA1c%, HDL and VLDL to the healthy group were (4.62 ± 0.41, 58.15 ± 3.19 and 16.13 ± 1.89) as shown in figures number 2 & 4.

The results showed a direct relationship between fasting blood sugar level and HbA1c% in blood, as shown in Figures 1&3, with a significant value (p < 0.001). Also, the results showed a direct relationship between the high levels of different lipids in patients with type2 Diabetes, as shown in figures 1-4.

Again the results showed a direct relationship between fasting blood sugar level (mean ± SEM) of FBS (109.12 ± 6.21) of group2 (HbA1c < 7%) & (220.08 ± 43.06) of group3 (HbA1c > 7%) respectively versus (86.51 ± 9.32) of control group (healthy group) and HbA1c % level in blood (mean ± SEM) of HbA1c% (6.56 ± 0.32) of group 2 (HbA1c < 7%) & (11.32 ± 0.21) of group3 (HbA1c > 7%) respectively versus (4.62 ± 0.41) of control group (healthy group), as shown in figures 1 & 3, with a significant value (p < 0.001).

Moreover, the values also explained that there is a direct relationship between the high blood levels of different lipids in patients with type 2 diabetic (mean ± SEM) of CT, TG and LDL (109.12 ± 6.21, 180.16 ± 18.75, 165.63 ± 20.63 and 104.51 ± 8.20) respectively of group2 (HbA1c < 7%) & CT, TG and LDL (220.08 ± 43.06, 270.18 ± 19.80, 210.33 ± 19.41 and 191.0 ± 16. 31) respectively of group3 (HbA1c > 7%) and HbA1c% level in blood (mean ± SEM) of HbA1c% (6.56 ± 0.32) of group 2 (HbA1c < 7%) & (11.32 ± 0.21) of group3 (HbA1c > 7%) respectively versus (4.62 ± 0.41) of control group (healthy group), as is clear in Figures 1-4 with a significant value (p < 0.001) as shown I table (5).

Table 5: Represents the mean ± S.E.M of F.B.S., CT, T.G. and LDL of type 2 diabetic patients (HbA1c < 7% and HbA1c > 7) of G1 compared to the healthy group (control).

Mean ± SD	S mg/d	mg/dl	mg/dl	L mg/dl
Healthy people G1	101.51 ± 5.32	40.36 ± 10.51	165.65 ± 22.13	107.08 ± 4.78
Patients G1 (HbA1c < 7)	109.12 ± 6.21	180.16 ± 18.75	165.63 ± 19.63	107.51 ± 8.20
Patients G1 (HbA1c > 7)	220.08 ± 7.06	270.18 ± 19.80	210.33 ± 15.41	184.03 ± 7.31

Again the results showed an opposite relationship between (mean ± SEM) of HDL level in blood (42.53 ± 2.98) of group 2 (HbA1c < 7%) and (37.53 ± 3.27) of group3 (HbA1c > 7%) respectively versus (58.15 ± 3.19) of control group (healthy group) and (mean ± SEM) of HbA1c% (6.56 ± 0.32) of group 2 (HbA1c < 7%) and (11.32 ± 0.21) of group 3 (HbA1c > 7%) versus (4.62 ± 0.41) of control group, as we can see in figures 2&4 with a significant value (p < 0.001) as shown I table (6).

Table 6: Represents the (mean ± S.E.M) of HbA1c%, HDL, and VLDL of type 2 diabetic patients (HbA1c < 7% and HbA1c > 7) compared to the healthy group (control).

Mean ± SD	A1c %	HDL mg/dl	VLDL mg/dl
Healthy people G1	4.62 ± 0.41	58.15 ± 3.19	13 ± 1.89
Patients (HbA1c < 7)	6.56 ± 0.32	42.53 ± 2.98	13 ± 8.40
Patients (HbA1c > 7)	11.32 ± 0.21	37.53 ± 3.27	42.06 ± 9.00

4. Discussion

Diabetic is the third most prominent reason to die worldwide and is accountable for many multiples affecting different body members⁽²⁾. Diabetes mellitus is considered a worldwide and nationally scourge, primarily because of raised rates of obesity. The results of our study explained that for subjects who are HbA1c < 7%, their (mean ± S.E.M.) of F.B.S., CT, T.G., VLDL and LDL for pre-diabetic (patient of group2) were higher than their non-diabetic, while HDL cholesterol values were found to be lower than the non-diabetics group1 (healthy group). Again group2 (HbA1c < 7%) of type 2 diabetic patients if we compared their (mean ± S.E.M.) of F.B.S., CT, T.G., VLDL and LDL with (mean ± S.E.M.) of F.B.S., CT, T.G., VLDL and LDL of group3 diabetic patients (HbA1c > 7%) were higher than their of group3, while HDL of subjects who are HbA1c < 7%, they are (mean ± S.E.M.) is higher than HDL of subjects who are HbA1c > 7% versus to healthy group (reverses relation) and the reasons can result due to the obesity which the last is turn out a worldwide plague. Fitness is a freelance danger operator for heart diseases in both sexes⁽⁷⁾.

Our study also explained the rise diffusion of hypercholesterolemia, hypertriglyceridemia and hence, bad fats rise in Patients with type 2 Diabetic (HbA1c > 7%, group 3 patients), immensely well-known dangerous agents that cause cardiovascular diseases. Insulin affects the liver apolipoprotein manufacture, where it regulates the enzymatic action of lipoprotein lipase (LpL) and cholesterol ester transfer protein. All these agents are likely to cause dyslipidemia in D.M.⁽²⁴⁾.

In addition, insulin deficiency minimizes the vigour of hepatic lipase and many proceedings in the production of biologically active LpL may be altered in D.M. So, indeed exists affirmative relation between plasma glucose and HbA1c to T.C. and T.G. levels, and all determined diabetic patients should be checked to ensure of cardiac regarding problems⁽²⁷⁻³⁰⁾. As a result, HbA1c control of the patient has strongly affected lipid profile levels, heart diseases, and stroke. Patients should be learning uniform control of lipid profiles and if set to be abnormal, should control glucose levels in blood, cholesterol and triglyceride very effectively^(31,32).

Therefore A1c would be used as a foreteller of dyslipidemia in type 2 diabetes mellitus and as a glycemic control marker. Also, the study said that early diagnosis of dyslipidemia would be used as preventative gauge for improved cardiovascular disease in type 2 diabetes⁽³³⁾.

5. Conclusion:

Results mention that the A1c level will be applied as a perfect operator for an estimate the fats of diabetic patients. So well glycemic dominance through anti-diabetes treatment and lifestyle change will minimize the danger of heart diseases and their multiples. Also, eating some healthy drinks such as green tea helps reduce fat levels, as green tea reduces HDL and LDL cholesterol⁽²⁾.

This double biomarker- A1c management and fats monitoring- can be used to check height fat danger patients for early diagnosis of abnormal lipids. Subsequently, we avoid heart diseases and their multiples by the timely intervention of the disease.

References

1. N. Senthilkumar et al. Correlation observation between HbA1C and Lipid profile in Type II Diabetes Mellitus Out-Patients. International Journal of Pharma Research & Review, May 2016;5(5):9-20.
2. Khalid S et al. The Relation between Overweight, Obesity and Plasma Lipids in Saudi Adults with Type 2 Diabetes. International Journal of Diabetes and Clinical Research. Aljabri et al. Int J Diabetes Clin Res 2015, 2:3.
3. Marouf et al. THE EFFECT OF THE COVID-19 PANDEMIC (CORONA VIRUS) ON HBA1C AND DAILY SUGAR LEVELS ON DIABETIC PATIENTS. COMMUNITY PRACTITIONER. MAY Volume 20 Issue 5.
4. Marouf et al. Determination of SDO Activity and LBSA in Serums of Benign and Malignant Breast Tumors. Annals of R.S.C.B., ISSN:1583-6258, Vol. 25, Issue 6, 2021, Pages. 4158 - 4164.
5. Marouf et al. A CLINICAL STUDY TO INVESTIGATE LIVER ENZYMES AND MINERALS IN ALCOHOLIC AND CIGARETTE SMOKER AMONG IRAQI MALES. Annals of Tropical Medicine & Public Health. Nov 2020 Vol. 23 Issue 19.
6. Riaz S et al. Obesity as risk factor and study of obesity related proteins in diabetes mellitus. African Journal of Biotechnology 2009, 8: 737-744.
7. Hubert HB et al. Obesity as an independent risk factor for cardiovascular disease. Circulation 1983, 67,968-977.
8. Amos Af et al. The rising global burden of Diabetes and its complications: estimates and projections to the year 2010. DiabetMed, 14 (Suppl.5), 1997, S1-S85.
9. Kayalvili Sanmugam. A Study of Lipid Profile Levels in Oral Cancer. 2015, 8.
10. Jinan Hussein Murtadha et al. Study of Liver Function and Lipid Profile Changes in Iraqi Cirrhotic patients. 2020, 13.
11. Hammoud T et al. Management of coronary artery disease: therapeutic options in patients with Diabetes. J Am Coll Cardiol, 36, 2000, 355-65.

12. Karthikeyan Murthy Kumar, Sheeja Varghese. Effect of Nonsurgical Periodontal Therapy on Serum Lipid Profile- Prospective Study.2019, 12.
13. Abbas SabbarDakhil. Association of the ATP-binding Cassette Transporter A1 Gene Polymorphism with Lipid Profile and Type 2 Diabetes Mellitus.2019, 12.
14. Gaziano TA, Gaziano JM. Global burden of cardiovascular diseases. In: Bonow RO, Mann DL Zipes DP, Libby P editors.Braunwald's Heart Disease: A textbook of Cardiovascular Medicine. Philadelphia: Saunders-Elsevier 2012;9:1-12.
15. Abbas SabbarDakhil. Association between Troponin and Lipid Profile Levels in patients with Chronic Heart Failure.2020, 13.
16. WaiWaiPhyo New et al. Serum Uric Acid, Lipid Profile and Atherogenic Index of Plasma in Dipper and Non-dipper Normotensive Subjects.2021, 14.
17. Stratton IM et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. *British Medical Journal* 2000;321:405-412.
18. Turner RC et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. *British Medical Journal* 1998;316:823-828.
19. Manikandan. R, Sarumathy. S. Clinical study on assessment of lipid Profile and renal function in type 2 Diabetic patients- A Retrospective Study. 2018, 11.
20. Baljinder Singh Bal et al. Study of Association between HbA1c Level and Lipid Profile in Type 2 Diabetes Mellitus. *Annals of International Medical and Dental Research*,2017; Vol (3), Issue (2).P36-39.
21. Alok Kumar Verma et al. Biochemical Studies on Serum Hb, Sugar, Urea and Lipid Profile under Influence of *Ocimum sanctum* L in Aged Patients. 2012, 5.
22. I.D.F. Diabetes Atlas, Sixth Edition, 2014.
23. P.Muraliswaran et.al. A correlative study of HbA1C and lipid profile parameters among type 2 diabetic population in a rural hospital in puducherry. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861*.Volume 15, Issue 9 Ver. XII (September). 2016).
- 24.S. V. Upasani et al. Traditional Indian spices useful in Diabetes Mellitus – an updated review. *Journal of Pharmaceutical & BioSciences*. 2013, Oct-Dec, 1(4):157-161.
25. AichaLaissaoui et al. HBA1C AS A PREDICTOR OF DYSLIPIDEMIA IN ALGERIAN TYPE 2 DIABETIC PATIENTS. *Romanian Journal of Diabetes Nutrition & Metabolic Diseases*, Vol. 23, no. 2, 2016.
- 26.Marouf et al. Comparison of mRT-PCR method with microscopy for *Giardia lamblia* diagnosis. *Annals of R.S.C.B.*, ISSN:1583-6258, Vol. 25, Issue 3, 2021, Pages. 7473 – 7477.
27. Pravin V Ingle et al. Dighore and PH. Patil. Clinical Impact of Thyroid Dysfunction in Patients with Diabetes Mellitus.*International Journal of Pharmaceutical and Chemical Sciences*. 2014, April-June, 3(2):327-334.
28. Singh. G and kumar. A, *Journal of exercise and physiotherapy*, 2011, vol.7, No.2: 99-102.
29. Erciyas F et al. Glycemic control, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. *Arch. Med. Res.* 2004; 35: 134-140.
30. Khan, H.A.et al. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. *Clin.Exp. Med.* 2007; 7: 24- 29.
31. JB Buse et al. *PP Erickson Diabetes ObesMetab.* 2004 Mar; 6(2): 133-156.
32. Ram VinodMahato et al., Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycatedhaemoglobin as a dual biomarker., *Biomedical Research* 2011; 22 (3): 375-380.
33. Selvin E et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med.* 2004;141:421–431.